​

Revance Therapeutics Ownership | Who Owns Revance Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Revance Therapeutics Ownership Summary

Revance Therapeutics is owned by 38.10% institutional investors, 8.56% insiders, and 53.34% retail investors. Blackrock is the largest institutional shareholder, holding 9.32% of RVNC shares. American Funds SMALLCAP World A is the top mutual fund, with 7.09% of its assets in Revance Therapeutics shares.

RVNC Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRevance Therapeutics38.10%8.56%53.34%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock8.57M9.32%$22.01M
Blackrock funding, inc. /de8.60M8.25%$26.14M
Beryl capital management5.94M5.70%$18.04M
Vanguard group5.63M5.40%$17.10M
Fil4.20M4.03%$12.76M
Alliancebernstein3.50M3.36%$10.63M
Squarepoint ops3.16M3.04%$9.62M
State street2.28M2.48%$5.87M
Magnetar financial2.56M2.45%$7.77M
Alpine associates management2.35M2.25%$7.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Beryl capital management5.94M4.08%$18.04M
Vazirani asset management350.00K3.30%$1.06M
Newtyn management1.81M0.96%$5.50M
Slotnik capital671.61K0.92%$2.04M
Fny investment advisers477.82K0.75%$1.45M
Gabelli & co investment advisers1.06M0.55%$3.22M
Alpine associates management2.35M0.43%$7.14M
Glazer capital1.95M0.40%$5.93M
Essex woodlands management457.08K0.32%$1.39M
Water island capital722.23K0.24%$2.20M

Top Buyers

HolderShares% AssetsChange
Beryl capital management5.94M4.08%5.94M
Glazer capital1.95M0.40%1.95M
Newtyn management1.81M0.96%1.81M
Millennium management1.55M0.00%1.40M
Blackrock8.57M0.00%1.25M

Top Sellers

HolderShares% AssetsChange
Capital world investors---13.94M
Franklin resources1.16M0.00%-3.62M
Polar capital---3.57M
Rubric capital management lp---2.66M
Tang capital management---2.50M

New Positions

HolderShares% AssetsChangeValue
Beryl capital management5.94M4.08%5.94M$18.04M
Glazer capital1.95M0.40%1.95M$5.93M
Newtyn management1.81M0.96%1.81M$5.50M
Slotnik capital671.61K0.92%671.61K$2.04M
Susquehanna fundamental investments551.22K0.02%551.22K$1.68M

Sold Out

HolderChange
Toronto dominion bank-5.00
Federated hermes-9.00
Nelson, van denburg & campbell wealth management group-17.00
Central trust-50.00
Assetmark-68.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202479-64.57%39,701,953-51.96%380.61%40-65.22%21-61.82%
Sep 30, 202422219.35%81,913,8280.64%781.00%11428.09%5530.95%
Jun 30, 2024185-8.87%81,390,810-2.08%880.92%88-15.38%42-12.50%
Mar 31, 2024203-6.02%83,118,62015.30%981.42%104-9.57%48-2.04%
Dec 31, 20232162.37%72,091,641-7.09%830.97%11511.65%49-9.26%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
American Funds SMALLCAP World A7.38M7.09%-
American Funds New Economy A6.33M6.08%-3.96K
Capital Group New Economy Comp6.33M6.08%-3.96K
Vanguard Total Stock Mkt Idx Inv2.97M2.84%-
iShares Russell 2000 ETF2.87M2.75%-
Fidelity Canadian Large Cap Sr B2.45M2.34%-
Franklin Biotechnology Discv A(acc)USD1.95M1.87%-
Arbitrage R1.59M1.53%164.00K
Federated Hermes MDT Small Cap Core IS1.51M1.45%516.10K
Federated Hermes MDT SCC Institutional1.51M1.45%516.10K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 18, 2024Hollander David CMO & Global Therapeutics LeadSell$16.30K
Apr 16, 2024Jordan Erica Chief Commercial OfficerSell$9.10K
Mar 18, 2024Sjuts Dustin S PresidentSell$46.45K
Mar 18, 2024Moxie Dwight CLO & GCSell$40.97K
Mar 18, 2024Schilke Tobin CFOSell$47.20K

Insider Transactions Trends

DateBuySell
2025 Q1--
2024 Q2-1
2024 Q113
2023 Q4--
2023 Q3-5

RVNC Ownership FAQ

Who Owns Revance Therapeutics?

Revance Therapeutics shareholders are primarily institutional investors at 38.10%, followed by 8.56% insiders and 53.34% retail investors. The average institutional ownership in Revance Therapeutics's industry, Biotech Stocks , is 68.48%, which Revance Therapeutics falls below.

Who owns the most shares of Revance Therapeutics?

Revance Therapeutics’s largest shareholders are Blackrock (8.57M shares, 9.32%), Blackrock funding, inc. /de (8.6M shares, 8.25%), and Beryl capital management (5.94M shares, 5.70%). Together, they hold 23.26% of Revance Therapeutics’s total shares outstanding.

Does Blackrock own Revance Therapeutics?

Yes, BlackRock owns 9.32% of Revance Therapeutics, totaling 8.57M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 22.01M$. In the last quarter, BlackRock increased its holdings by 1.25M shares, a 17.13% change.

Who is Revance Therapeutics’s biggest shareholder by percentage of total assets invested?

Beryl capital management is Revance Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.08% of its assets in 5.94M Revance Therapeutics shares, valued at 18.04M$.

Who is the top mutual fund holder of Revance Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Revance Therapeutics shares, with 7.09% of its total shares outstanding invested in 7.38M Revance Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools